Search

Displaying results 3921 - 3930 of 8698 in total
  1. Drug

    Streptococcus pneumoniae type 2 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10320
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  2. Drug

    Streptococcus pneumoniae type 8 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10326
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  3. Drug

    Streptococcus pneumoniae type 10a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10329
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  4. Drug

    Streptococcus pneumoniae type 11a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10330
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  5. Drug

    Streptococcus pneumoniae type 20 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10338
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  6. Drug

    Streptococcus pneumoniae type 22f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10339
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  7. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod]. … [A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Halothane

    go.drugbank.com/drugs/DB01159
    ApprovedVet approvedWithdrawn

    Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required.

    Categories: NMDA Receptor Antagonists, Cytochrome P-450 Substrates
  9. Pathway

    Disopyramide Cardiac Action Pathway

    smpdb.ca/view/SMP0126247
    Drug action

    Some side effects of using disopyramide may include dizziness, difficulty urinating, dry mouth, and nausea.

    Drugs: Disopyramide · Potassium cation · Calcium · Cyclic adenosine monophosphate
    Enzymes: Putative Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1,2-glucosyltransferase, Ryanodine receptor 2
  10. Pathway

    Mexiletine Action Pathway (New)

    smpdb.ca/view/SMP0126263
    Drug action

    Mexiletine is a class 1B antiarrhythmic agent used in the treatment of documented ventricular arrhythmias that warrant treatment. Mexiletine (INN) (sold under the brand names Mexitil and Namuscla) is a medication used to treat abnormal h...

    Drugs: Mexiletine · Potassium cation · Calcium · Cyclic adenosine monophosphate
    Enzymes: Putative Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1,2-glucosyltransferase, Ryanodine receptor 2